AVITA Medical
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of AVITA Medical generated cash of -$22,747,000, which is more than the previous year. Cash used in financing activities reached the amount of $77,057,000 last year. Net change in cash is therefore $53,466,000.
Cash Flow
| 2010 | -1.61M | -71.10K | 1.87M |
|---|---|---|---|
| 2011 | -2.92M | -89.2K | 12.95M |
| 2012 | -4.26M | -77.4K | -97.14K |
| 2016 | -7.93M | -47.84K | 9.36M |
| 2018 | -17.51M | -493.15K | 28.77M |
| 2020 | -32.96M | -1.22M | 111.65M |
| 2021 | -22.74M | -847K | 77.05M |
RCEL Cash Flow Statement (2010 β 2020)
| 2020 | 2019 | 2017 | 2015 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 20.37M | 29.02M | 3.79M | 2.96M | 12.96M | 4.13M | 2.95M |
Operating activities | |||||||
Net income | -42.03M | -60.90M | -17.20M | -7.77M | -7.76M | -1.92M | -5.11M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 465K | 673.78K | 148.62K | 83.72K | 521.93K | 650.87K | 517.57K |
Stock-based compensation expense | 16.59M | 24.04M | 1.96M | 956.65K | 0 | 0 | 0 |
| Deferred income tax benefit | 16.59M | 24.04M | 1.96M | 956.65K | 0 | 0 | 0 |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | -729K | -1.05M | -36.47K | -516.05K | 0 | 0 | 0 |
Inventories | -468K | -678.13K | -127.00K | -776.10K | 0 | 0 | 0 |
Accounts payable | 2.30M | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by operating activities | -22.74M | -32.96M | -17.51M | -7.93M | -4.26M | -2.92M | -1.61M |
Investing activities | |||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -847K | -854.91K | -493.15K | -48.28K | -77.4K | -89.2K | -71.10K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -847K | -1.22M | -493.15K | -47.84K | -77.4K | -89.2K | -71.10K |
Financing activities | |||||||
Common Stock Issued | 81.70M | 0 | 0 | 0 | 0 | 13.37M | 1.68M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | -94.92K | -217.6K | -50K |
Repayments of term debt | -42K | -60.85K | -82.41K | 0 | 0 | -965.12K | -354.11K |
Cash used in financing activities | 77.05M | 111.65M | 28.77M | 9.36M | -97.14K | 12.95M | 1.87M |
Net Change In Cash | 53.46M | 77.97M | 11.05M | 1.20M | -4.54M | 9.40M | 330.34K |
Cash at end of period | 73.84M | 106.99M | 14.84M | 4.17M | 8.42M | 13.54M | 3.28M |
| Data source | Data source |